Nothing Special   »   [go: up one dir, main page]

Kang et al., 2022 - Google Patents

In vitro inactivation of respiratory viruses and rotavirus by the oral probiotic strain weissella cibaria CMS1

Kang et al., 2022

View HTML
Document ID
16063238073936658359
Author
Kang M
Park G
Publication year
Publication venue
Probiotics and Antimicrobial Proteins

External Links

Snippet

Abstract Weissella cibaria CMS1 (oraCMS1) has been commercially used in Korea as an oral care probiotic for several years. Human respiratory syncytial virus (RSV) and the influenza A virus (H1N1) are representative viruses that cause infantile lower respiratory …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00—Cosmetic or similar toilet preparations
    • A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Bustamante et al. Probiotics and prebiotics potential for the care of skin, female urogenital tract, and respiratory tract
Stavropoulou et al. Probiotics in medicine: a long debate
Luoto et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial
Li et al. Efficacy and safety of probiotics in the treatment of C andida‐associated stomatitis
Meurman et al. Probiotics: contributions to oral health
Angelakis et al. Related actions of probiotics and antibiotics on gut microbiota and weight modification
Sanders How do we know when something called “probiotic” is really a probiotic? A guideline for consumers and health care professionals
Lenoir-Wijnkoop et al. Probiotic and prebiotic influence beyond the intestinal tract
Hsieh et al. Eradication of H elicobacter pylori Infection by the Probiotic Strains L actobacillus johnsonii MH‐68 and L. salivarius ssp. salicinius AP‐32
Lin et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study
Iniesta et al. Probiotic effects of orally administered Lactobacillus reuteri‐containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial
Wang et al. Probiotics to prevent respiratory infections in nursing homes: a pilot randomized controlled trial
Jones et al. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors
Sur et al. Role of probiotic in preventing acute diarrhoea in children: a community-based, randomized, double-blind placebo-controlled field trial in an urban slum
Fujita et al. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: a multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population
Jäsberg et al. Bifidobacteria inhibit the growth of Porphyromonas gingivalis but not of Streptococcus mutans in an in vitro biofilm model
Babina et al. The effect of oral probiotics (Streptococcus salivarius K12) on the salivary level of secretory immunoglobulin a, salivation rate, and oral biofilm: A pilot randomized clinical trial
Kang et al. In vitro inactivation of respiratory viruses and rotavirus by the oral probiotic strain weissella cibaria CMS1
Lin et al. Viable and heat-killed probiotic strains improve oral immunity by elevating the IgA concentration in the oral mucosa
Radicioni et al. Survival of L. casei DG®(Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population
Moghadam et al. Three-decade failure to the eradication of refractory Helicobacter pylori infection and recent efforts to eradicate the infection
Kavitha et al. Evaluation of Streptococcus mutans serotypes e, f, and k in saliva samples of 6–12-year-old school children before and after a short-term daily intake of the probiotic lozenge
Bisson et al. Preventive effects of different probiotic formulations on travelers’ diarrhea model in wistar rats: preventive effects of probiotics on TD
Magdy et al. Isolation of multidrug-resistant Helicobacter pylori from wild houseflies Musca domestica with a new perspective for the treatment
İnce et al. Salmonella gastroenteritis in children (clinical characteristics and antibiotic susceptibility): comparison of the years 1995-2001 and 2002-2008